Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cell-Arthrix is a multi-ingredient nutraceutical supplement primarily developed for veterinary use to support joint health and mobility in dogs and cats, though human formulations also exist. Produced by Kala Health, the product contains a synergistic blend of glucosamine hydrochloride, chondroitin sulfate, methylsulfonylmethane (MSM), and buffered Vitamin C (Ester-C). Its mechanism of action involves providing essential building blocks for the synthesis of the articular cartilage matrix and inhibiting degradative enzymes like matrix metalloproteinases. Additionally, MSM acts as an organic sulfur donor to support connective tissue integrity and modulate inflammatory pathways, such as NF-kB signaling. It is widely utilized for the management of osteoarthritis, hip dysplasia, and general age-related joint stiffness in companion animals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cell-Arthrix.